Naujas genetinis testas parodantis, ar reikalinga prostatos biopsija.

Naujas genetinis testas parodantis, ar reikalinga prostatos biopsija.

250.00 EUR In stock Buy at Merchant

This non-invasive prostate cancer diagnostic test uses molecular analysis of prostate fluid to detect biomarkers PCA3 and TMPRSS2:ERG, which indicate the risk of clinically significant prostate cancer, potentially reducing unnecessary biopsies by up to 45%.

  • The description claims that this test can reduce unnecessary biopsies by up to 45%.
  • The description claims that the test detects biomarkers PCA3 and TMPRSS2:ERG.

AI Readiness

Good foundation, but some important product data is still missing.

66%
4 important fields missing Claim to view full AI report
Data sourced from www.urolita.lt. Last updated: The description was auto-generated by an AI model based on the merchant's description. It may not be accurate or complete.
Claim www.urolita.lt to see AI Product Health

Takes ~2 minutes. No storefront changes.